Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CHAARTED: Docetaxel + ADT vs ADT alone in Metastatic Hormone-sensitive Prostate Cancer
NCT00309985Phase 3Completed
- Sponsor
- ECOG-ACRIN Cancer Research Group
- Start
- Sep 2006
- Primary completion
- Dec 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of docetaxel in prostate cancer (PCa), sponsored by ECOG-ACRIN Cancer Research Group. Started Sep 2006; status: completed.
02
Drugs
docetaxel
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT00309985.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00309985.